SCHEMBL18623933

SCHEMBL18623933

CCOC(=O)[C@H](F)C(C)(C)c1ccccc1F

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PIN1 Q13526 1/20 0.40
NPC1 O15118 3/20 0.39
SMN1; SMN2 Q16637 3/20 0.39
RAB9A P51151 2/20 0.39
ALDH1A1 P00352 2/20 0.39
KDM4E B2RXH2 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
MEN1 O00255 1/20 0.39
KMT2A Q03164 1/20 0.39
TSHR P16473 2/20 0.39
POLB P06746 1/20 0.38
NLRP3 Q96P20 1/20 0.38
ADRB2 P07550 4/20 0.37
ADRB1 P08588 4/20 0.37
ADRB3 P13945 4/20 0.37
MMP8 P22894 1/20 0.37
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC2 Q92769 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21677216 0.85 NPC1 (0.40) PIN1NPC1SMN1; SMN2RAB9AALDH1A1
SCHEMBL17168999 0.85 NPC1 (0.40) PIN1NPC1SMN1; SMN2RAB9AALDH1A1
SCHEMBL18636850 0.78 CTSS (0.38) NPC1SMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL21677270 0.78 CTSS (0.38) NPC1SMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL1625075 0.78 PIN1 (0.39) PIN1NPC1SMN1; SMN2RAB9AALDH1A1
SCHEMBL12982216 0.77 BACE1 (0.36) NPC1SMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL2588861 0.77 BACE1 (0.36) NPC1SMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL2589641 0.77 BACE1 (0.36) NPC1SMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL12981966 0.77 BACE1 (0.36) NPC1SMN1; SMN2RAB9AALDH1A1KDM4E
SCHEMBL18113457 0.76 PIN1 (0.45) PIN1NPC1SMN1; SMN2RAB9AALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170073337-A1 DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY SHIONOGI & CO., LTD. (JP) 2017-03-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170073337-A1 DIHYDROTHIAZINE AND DIHYDROOXAZINE DERIVATIVES HAVING BACE1 INHIBITORY ACTIVITY BACE1, BACE2, APP PIN1 3003/4885NPC1 236/4885SMN1; SMN2 2423/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.